Payment overview · 2025
General Payments
$1,242.44
52 reported records · 17 companies
Healthcare provider profile · identity verified
Stanley S. Tu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, CA · NPI 1215011879
Verified facts
What the public records show
CMS Open Payments records show Stanley S. Tu, M.D. received $1,242.44 in general payments during 2025 across 52 reported records.
HARMONY BIOSCIENCES LLC accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $182.18 | 14.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $167.77 | 13.5% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $156.88 | 12.6% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $143.34 | 11.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $118.83 | 9.6% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $77.01 | 6.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $74.03 | 6.0% | 4 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $61.66 | 5.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $58.77 | 4.7% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $40.23 | 3.2% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $32.76 | 2.6% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $29.27 | 2.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.64 | 1.9% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $21.53 | 1.7% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.90 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.52 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.12 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,242.44 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $182.18 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $147.99 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $143.34 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $129.43 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $118.83 | 6 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $77.01 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $74.03 | 4 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $58.77 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $32.76 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Sleep Service Normalized: sleep service |
Device | Philips North America LLC | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 643 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 69 |
| Losartan Potassium | Losartan Potassium | 275 | 76 |
| Metformin Hcl | Metformin Hcl | 275 | 74 |
| Lisinopril | Lisinopril | 207 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 56 |
| Omeprazole | Omeprazole | 147 | 50 |
| Alprazolam | Alprazolam | 111 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 23 |
| Gabapentin | Gabapentin | 87 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 43 |
| Azithromycin | Azithromycin | 83 | 72 |
| Simvastatin | Simvastatin | 83 | 25 |
| Glipizide | Glipizide | 82 | 19 |
| Allopurinol | Allopurinol | 80 | 17 |
| Carvedilol | Carvedilol | 75 | 21 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Furosemide | Furosemide | 71 | 21 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 16 |
| Famotidine | Famotidine | 63 | 19 |
| Alendronate Sodium | Alendronate Sodium | 59 | 12 |
| Ozempic | Semaglutide | 58 | suppressed |
| Irbesartan | Irbesartan | 57 | 17 |
| Benazepril Hcl | Benazepril Hcl | 55 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 14 |
| Eliquis | Apixaban | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Atenolol | Atenolol | 50 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 12 |
| Ezetimibe | Ezetimibe | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | 13 |
| Finasteride | Finasteride | 40 | 13 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | 16 |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Cephalexin | Cephalexin | 21 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,242.44 · 52 records | HARMONY BIOSCIENCES LLC | ACTHAR, CHARTIS CATHETER, Cologuard Collection Kit, JASCAYD, LUMRYZ, MI CANCER SEEK, NUCALA, OFEV, Ohtuvayre, Ozempic, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, Rybelsus, Sleep Service, Sunosi, TRELEGY ELLIPTA, Tyvaso, Vest Therapy Und, WAKIX, Xhance, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error